Mike has more than 35 years of broad-based financial and operations experience including 15 years in the life sciences sector, most recently as Senior Director, Business & Sales Operations of Smith and Nephew's Biotherapeutics' Division.
Mike began his professional career at Arthur Andersen & Co., followed by senior financial positions in oil and gas exploration and production, ranching and financial asset management. He has also served as a board advisor for a pharmaceutical manufacturer and railroad equipment manufacturer. At HealthPoint, where he served as Senior Director of Finance & Administration and as Controller, Mike was instrumental in developing the business from a private startup and in closing the $770 million acquisition by Smith & Nephew.
Mike earned his Bachelor of Business Administration in Accounting from Texas Christian University.
A seasoned leader with market growth achievements across a wide range of health care businesses, Rob has leveraged his broad experience to lead the full range of market development processes—from opportunity assessment and product development through international brand building. Rob works with the executive management team to lead the business, establish objectives, and define and execute the business strategy. He leads corporate and brand marketing from business/product development through brand building, product growth and value creation, and develops the initiatives, programs and tools that drive sales.
Rob spent 23 years with Johnson & Johnson, working in research and development, quality assurance, operations, and sales and marketing at four operating companies. He has worked an additional 12 years in the medical and surgical industry and is accomplished in strategic and portfolio planning, lifecycle management, launching new products and driving revenue growth. Throughout his career, Rob has received 16 achievement awards for his work in sales, business development, product development, and business and marketing processes.
Rob earned his Bachelor of Science in Resource Management from Rutgers University, and his Master of Business Administration from Baylor University.
Zach is a highly competitive, dynamic medical sales leader with 15 years of private and large corporate leadership experience. He has a passion for creating winning teams through identifying, attracting and retaining top sales talent. Zach leads teams to success by maximizing each individual’s abilities, giving well-communicated direction and removing barriers to success. Zach is driven to help patients and care providers through delivery of superior clinical outcomes.
As a member of the executive management team, Zach is responsible for driving the sales team to perform and prioritizing the customers and patients we serve. He leads the development and implementation of strategies for market expansion and entry into new call points that will facilitate penetration of U.S. markets and drive sales growth for the company’s product portfolio. He actively works with customers and business partners to build relationships, as well as with the sales organization to drive their deployment and growth.
Zach spent the last 11 years in the medical industry with Healthpoint Biotherapeutics and most recently with Smith & Nephew. He has a broad array of experience including marketing, market research, customer-facing sales, region sales management and sales training.
Zach received a Bachelor of Science from Indiana University while competing in track and field.
Sherlene is an accomplished executive with a record of achievements across several industries. She has experience in the medical device and biopharmaceuticals industry in brand management, product development, strategic marketing, and business development, and has manufacturing and operations expertise as well.
Sherlene’s primary responsibility is for the leadership, strategy, management, and implementation of product development programs including FDA compliance, design history and production. Additionally, she is responsible for the planning and management of the full spectrum of marketing activities including positioning, pricing, promotion and distribution activities, as well as maintaining customer relationships and serving as the voice of the customer.
Sherlene is the President and Owner of Cura Business Group, LLC (CBG), a specialty consulting firm to the healthcare industry. Prior to establishing CBG, she worked for Fortune 100 companies where she focused on commercial marketing and portfolio development for biologics and devices in the acute and non-acute wound care markets.Sherlene is also the owner of Confectionery Corner, an award-winning bakery in Arlington, Texas.
Sherlene received her Bachelor of Business Administration in Management from the University of Texas at Arlington.
Elected chairman of the board in February 2017, John has served as Acting Chairman since November 2015 and has served on the company’s board of directors since December 2014. Throughout his tenure, John’s expertise in turnaround opportunities has proven instrumental in the acquisition of more than 20 companies. He has also led efforts to take companies public through reverse merger transactions.
John’s experience in turnarounds, mergers and acquisitions began during his time as Chief Operating Officer of Enduro Systems, Inc., and as Chief Financial Officer of Deep Down, Inc., he completed the reverse merger public transaction. John is a founding member of Twin Oaks Equity, LLC, a firm specializing in corporate turnarounds, mergers and acquisitions.
John earned a Bachelor of Science in mechanical engineering from Iowa State University.
Jim began his illustrious 53-year career with J.J.B. Hilliard, W.L. Lyons, LLC (Hilliard Lyons), as an advisor/trader; Hilliard Lyons is a full-service financial asset management firm headquartered in Louisville, Ky. With recognized leadership skills and demonstrated integrity, Jim rose to lead the Company as Chairman and Chief Executive Officer. Under Jim’s leadership, Hilliard Lyons grew to more than 2,200 employees, with 85 offices in thirteen Midwestern states and managed assets in excess of $35 billion.
Jim was an initial investor and board member of Royal Gold, Inc., for 24 years. He has served as Chairman of SenBanc Fund, board member of DataBeam, Inc., and board member of the Securities Industry Association (SIA). He has also served as a past member of the nominating committee of the New York Stock Exchange and as Chairman of the SIA’s Regional Firms Committee.
Jim has proudly served his alma mater, the University of Kentucky, in distinguished roles as a member of the Board of Trustees, Vice Chairman and Chairman of the Finance Committee, and Chairman of the Presidential Search Committee. In addition, he was Chairman of a hospital’s investment committee with investable assets in excess of $1.2 billion.
Jim earned his Bachelor of Science in Mechanical Engineering and his Master of Business Administration degrees at the University of Kentucky.
Denny is a long-time investor in pharmaceutical and medical device companies, as well as a past director of a pharmaceutical company. He has served as President of Howell & Howell Contractors Inc., a renovation and industrial/commercial painting contractor, since 1972. He is the Secretary/Treasurer of LCM Constructors, Inc., a general construction company; Secretary/Treasurer of SemperFi Constructors, LLC., a service-disabled, veteran-owned small business; Chairman of Keller Manufacturing Company; Chairman of PDD, LLC; and a Trustee of Lindsey Wilson College in Columbia, Ky.
With a clean balance sheet and strategic growth initiatives underway, we’re poised for continued revenue growth from our patent-protected and FDA-cleared products.
WNDM Medical Inc., is an emerging commercial stage company with its primary products in the $11 billion U.S. consumable medical device market and in the $1.5 billion biomaterials market. Our primary focus is the distribution of our unique, patented CellerateRX® Surgical Activated Collagen® Adjuvant, which is FDA-cleared and indicated for all surgical and traumatic wounds, except third degree burns. We have also received FDA-clearance for HemaQuell® Resorbable Bone Hemostat.
We project rapid revenue growth based on increasing sales from our FDA-cleared CellerateRX® Surgical Activated Collagen® Adjuvant, as well as anticipated revenues from our FDA-cleared HemaQuell® Resorbable Bone Hemostat.
Valid in most surgical specialties, our products are cost-effective across the continuum of care. They are supported by our growing internal sales management team and a network of seasoned health care distributors.
WNDM Medical is traded on the OTCQB capital markets under the ticker symbol WNDM.
John Siedhoff, Chairman
Securities Transfer Corporation
2591 Dallas Parkway, Suite 102
Frisco, TX 75034
Certified Public Accounting Firm
9801 Westheimer, Suite 1100
Houston, TX 77042
WNDM Medical, Inc.
1200 Summit Avenue, Suite 414
Fort Worth, Texas 76102
Over the years, we’ve expanded beyond wound care, and we felt it was time our company name reflected the breadth of products we offer.
We have a new website address—WNDM.com—and a new logo. The high level of quality and effectiveness you’ve found in our products will remain the same.
We have a new management team in place that is committed to growing our product offerings. Our new name is a reflection of our long-term vision for growth, fueled by our commitment to develop products to meet the needs of healthcare providers and patients.